🟢 GRAIL is trading 17.6% up today ahead of September 23 FDA advisory committee review

GRAIL is trading at $95.00, +17.62% (17.6% up) after investors positioned ahead of the September 23 FDA advisory committee review of Galleri’s premarket approval application.

• The FDA says the panel will discuss, recommend, and vote on the application.
• The move extends GRAIL’s climb from $75.53 on September 14 to $80.77 on September 18, supported by broader risk-on sentiment.
• The advisory vote is a recommendation, not a final FDA approval.